European Equity pre-Market Summary – 12th October 2026: European bourses set for a firmer open; NDX1 GY +3.6% on a positive update

The BMPS board meeting convened to weigh Intesa's raised offer is the item with the longest institutional memory: unsolicited or contested Italian bank approaches have historically run through extraordinary board sessions, antitrust and golden-power review in Rome, and a slow sequence of sweetened terms, and the pattern in this dossier specifically is one of successive revisions rather than a clean single-step bid. Whether the board characterises the revised offer as adequate or invites further improvement is the tell that has mattered in comparable bank-consolidation episodes, more than the headline premium itself. The Inwit take-private financing story follows the established tower-sector playbook, where sponsor and infrastructure-fund ownership of network assets has repeatedly ended in delisting once leverage and cost of capital lined up; the financing arrangement stage, rather than the announcement, has tended to be the point of failure or confirmation. Among the single-stock prints, the Nordex order intake is the kind of update that in past cycles has been traded against backlog quality and margin conversion rather than headline megawatts, and the wind-turbine peer set typically moves in sympathy on the day before differentiating on pricing. The Var Energi guidance cut reads as the operational side of a North Sea producer resetting expectations, where the follow-on question is capex and dividend capacity rather than the production number alone. The AstraZeneca miss-with-numerical-improvement and Roche readout fit the standard biotech pattern: a failed primary endpoint with directional data has historically been treated as a pipeline setback but not a valuation event, with attention shifting to regulatory intent. The next catalysts are the BMPS board outcome, any Intesa response, and confirmation of Inwit financing terms.